Emergent Stock Today


USD 31.04  0.51  1.67%   

Market Performance
0 of 100
Odds Of Distress
Less than 38
Emergent Biosolutions is selling at 31.04 as of the 30th of June 2022; that is 1.67 percent up since the beginning of the trading day. The stock's lowest day price was 30.11. Emergent Biosolutions has about a 38 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Emergent Biosolutions are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of May 2022 and ending today, the 30th of June 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
15th of November 2006
Health Care
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. The company has 50.24 M outstanding shares of which 3.36 M shares are currently shorted by investors with about 3.39 days to cover. More on Emergent Biosolutions

Moving together with Emergent Biosolutions

0.79ACBAurora Cannabis Fiscal Year End 26th of September 2022 PairCorr
0.78CGCCanopy Growth Corp TrendingPairCorr
0.91HEXOHexo Corp Fiscal Year End 4th of November 2022 PairCorr

Moving against Emergent Biosolutions

0.61TATT Inc Earnings Call  In Three WeeksPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Emergent Biosolutions Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Emergent Biosolutions' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Emergent Biosolutions or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Emergent Biosolutions generated a negative expected return over the last 90 days
Emergent Biosolutions has high historical volatility and very poor performance
Emergent Biosolutions was previously known as EMERGENT BIOSOLUTIONS INC and was traded on New York Stock Exchange under the symbol EBS.
Emergent Biosolutions has a strong financial position based on the latest SEC filings
Over 88.0% of the company shares are held by institutions such as insurance companies
Latest headline from seekingalpha.com: U.S. to widen access to monkeypox vaccines - Seeking Alpha
Older SymbolEBS
President CEO, DirectorDaniel AbdunNabi
Thematic IdeaPharmaceutical Products (view all)
Fama & French Classification
Average Analyst Recommendation
Analysts covering Emergent Biosolutions report their recommendations after researching Emergent Biosolutions' financial statements, talking to executives and customers, or listening in on Emergent Biosolutions' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Emergent Biosolutions. The Emergent consensus assessment is calculated by taking the average forecast from all of the analysts covering Emergent Biosolutions.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Emergent Biosolutions based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Emergent Biosolutions financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 7 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares45.9 M53.5 M
Fairly Down
Slightly volatile
Weighted Average Shares Diluted47.6 M54.1 M
Fairly Down
Slightly volatile
Net Cash Flow from Operations346.4 M321.1 M
Significantly Up
Slightly volatile
Total Assets3.2 BB
Significantly Up
Slightly volatile
Total Liabilities1.4 B1.3 B
Significantly Up
Slightly volatile
Current Assets1.4 B1.3 B
Significantly Up
Slightly volatile
Current Liabilities403.3 M373.8 M
Significantly Up
Slightly volatile
Total Debt668.2 M841 M
Significantly Down
Slightly volatile
Return on Average Assets6.837.9046
Fairly Down
Very volatile
Gross Margin72.0757.7453
Fairly Up
Slightly volatile
Asset Turnover0.630.6137
Fairly Up
Very volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Emergent Biosolutions' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Emergent Biosolutions' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Emergent Biosolutions' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Emergent Biosolutions' financial leverage. It provides some insight into what part of Emergent Biosolutions' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Emergent Biosolutions' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Emergent Biosolutions deploys its capital and how much of that capital is borrowed.
Emergent Biosolutions cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 861.5 M in debt with debt to equity (D/E) ratio of 0.55, which is OK given its current industry classification. Emergent Biosolutions has a current ratio of 4.32, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Emergent Biosolutions until it has trouble settling it off, either with new capital or with free cash flow. So, Emergent Biosolutions' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Emergent Biosolutions sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Emergent to invest in growth at high rates of return. When we think about Emergent Biosolutions' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

346.45 MillionShare
Emergent Biosolutions (EBS) is traded on New York Stock Exchange in USA. It is located in 400 Professional Drive, Suite 400, Gaithersburg, MD 20879, United States and employs 2,416 people. Emergent Biosolutions was previously known as EMERGENT BIOSOLUTIONS INC and was traded on New York Stock Exchange under the symbol EBS. Emergent Biosolutions is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with total capitalization of 1.53 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Emergent Biosolutions's market, we take the total number of its shares issued and multiply it by Emergent Biosolutions's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Emergent Biosolutions runs under Healthcare sector within Drug Manufacturers—Specialty & Generic industry. The entity has 50.24 M outstanding shares of which 3.36 M shares are currently shorted by investors with about 3.39 days to cover. Emergent Biosolutions has about 436 M in cash with 278.7 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.68.
Check Emergent Biosolutions Probability Of Bankruptcy
Emergent Biosolutions retains a total of 50.24 Million outstanding shares. The majority of Emergent Biosolutions outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Emergent Biosolutions to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Emergent Biosolutions. Please pay attention to any change in the institutional holdings of Emergent Biosolutions as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Emergent Ownership Details

Emergent Stock Price Odds Analysis

What are Emergent Biosolutions' target price odds to finish over the current price? In regard to a normal probability distribution, the odds of Emergent Biosolutions jumping above the current price in 90 days from now is about 75.86%. The Emergent Biosolutions probability density function shows the probability of Emergent Biosolutions stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 1.5267 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Emergent Biosolutions will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Emergent Biosolutions is significantly underperforming DOW.
  Odds Below 31.04HorizonTargetOdds Above 31.04
24.05%90 days
Based on a normal probability distribution, the odds of Emergent Biosolutions to move above the current price in 90 days from now is about 75.86 (This Emergent Biosolutions probability density function shows the probability of Emergent Stock to fall within a particular range of prices over 90 days) .

Emergent Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Emergent Biosolutions that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Emergent Biosolutions' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Emergent Biosolutions' value.
InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares8.7 M358.5 M
Vanguard Group IncCommon Shares5.2 M211.7 M
View Emergent Biosolutions Diagnostics

Emergent Biosolutions Historical Income Statement

Emergent Biosolutions Income Statement is one of the three primary financial statements used for reporting Emergent's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Emergent Biosolutions revenue and expense. Emergent Biosolutions Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Emergent Biosolutions Operating Income is relatively stable at the moment as compared to the past year. Emergent Biosolutions reported last year Operating Income of 352.6 Million. As of 06/30/2022, Revenues is likely to grow to about 1.9 B, while Interest Expense is likely to drop slightly above 27.4 M. View More Fundamentals

Emergent Stock Against Markets

Picking the right benchmark for Emergent Biosolutions stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Emergent Biosolutions stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Emergent Biosolutions is critical whether you are bullish or bearish towards Emergent Biosolutions at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Emergent Biosolutions without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Optimization Now


Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Module

Emergent Biosolutions Corporate Directors

Emergent Biosolutions corporate directors refer to members of an Emergent Biosolutions board of directors. The board of directors generally takes responsibility for the Emergent Biosolutions' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Emergent Biosolutions' board members must vote for the resolution. The Emergent Biosolutions board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Sue Bailey - Independent DirectorProfile
Jerome Hauer - Independent DirectorProfile
Kathryn Zoon - Independent DirectorProfile
Seamus Mulligan - DirectorProfile

Investing Emergent Biosolutions

You need to understand the risk of investing before taking a position in Emergent Biosolutions. The danger of trading Emergent Biosolutions is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Emergent Biosolutions is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Emergent Biosolutions. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Emergent Biosolutions is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Investing Opportunities. Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Emergent Stock analysis

When running Emergent Biosolutions price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
CEO Directory
Screen CEOs from public companies around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
1.6 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine Emergent Biosolutions value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.